Evidence mapPaperPMID 40115485Full record

ArticleCentral European journal of urology2024

Baseline characteristics and clinical outcomes of prostate cancer patients on delayed palliative management: a PIONEER analysis based on big data.

Lana Yh Lai, Vasileios Sakalis, Christos Chatzichristos, Irene de la Parra, Carl Steinbeisser, Asieh Golozar, Bertrand de Meulder, Ayman Hijazy, Robert Snijder, Qi Feng and 7 more

Abstract read
In one paragraph

Article in Central European journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Lana Yh LaiDivision of Informatics, Imaging and Data Sciences, University of Manchester, United Kingdom.
Vasileios SakalisHippokrateion General Hospital of Thessaloniki, Greece.
Christos ChatzichristosClinical Innovation Research & Janssen Pharmaceutica, Beerse, Belgium.
Irene de la ParraDepartment of Urology, Hospital Clinico San Carlos, Madrid, Spain.
Carl SteinbeisserCollaborate Project Management, Munich, Germany.
Asieh GolozarOdysseus Data Services, Cambridge, USA.
Bertrand de MeulderEuropean institute for systems biology and medicine, Lyon, France.
Ayman HijazyEuropean institute for systems biology and medicine, Lyon, France.
Robert SnijderAstellas Pharma Europe Ltd, Addlestone, United Kingdom.
Qi FengAstellas Pharma, Inc., Northbrook, IL, USA.
Thomas FalconerDepartment of Biomedical Informatics, Columbia University, New York, NY, USA.
Philip CornfordLiverpool University Hospitals, Liverpool, England.
Anders BjartellDepartment of Translational Medicine, Faculty of Medicine, Lund University, Sweden.
Susan Evans-AxelssonBayer AG, Berlin, Germany.
James N'DowAcademic Urology Unit, University of Aberdeen, Scotland, United Kingdom.
Giorgio GandagliaDepartment of Urology and Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Hospital, Milan, Italy.
Juan Gómez RivasDepartment of Urology, Hospital Clinico San Carlos, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Delayed palliative management (DPM) is an alternative for prostate cancer (PCa) patients with poor performance status, or those who received radical treatment but progressed and no longer meet the criteria for curative treatment. PIONEER is a large network of federated data analytic platforms in PCa that aims to improve its care through the application of big data analytics. The objective of this study was to describe clinical baseline characteristics and outcomes of PCa patients receiving DPM using big data. Material and methods: Descriptive study of patients on DPM from four databases in PIONEER (Pharmetrics Plus, Optum Clinformatics, Marketscan and Columbia University Irving Medical Center (CUIMC)). Baseline characteristics, including comorbidities (hypertension, type 2 diabetes (T2DM), asthma/chronic obstructive pulmonary disease (COPD) and obesity), were stratified by age. Outcomes of interest were annual emergency department (ED) visits, hospitalization and symptomatic progression. Additional outcomes were time to death, hospitalization and time to symptomatic progression for CUIMC. Results: We included 13246 men with a median age of 68-75 and Charlson Comorbidity index of 6-8. The three most common comorbidities were hypertension (80-93% [>80 years] vs 69-80% [55-80 years] vs 59-64% [<55 years]), T2DM (29-41% [>80 years] vs 26-38% [55-80 years] vs 23-26% [<55 years] and asthma/COPD (28-37% [>80 years] vs 19-30% [55-80 years] vs 16-19% [<55 years]). ED visits and hospitalizations were highest in the first year of follow-up (19-33% and 21-48% respectively). The median time to death was 548 days (IQR 1265 days) and to symptomatic progression was 408 days (IQR 1125 days) in CUIMC. Conclusions: Men on DPM were in their mid-seventies, with the three most common comorbidities being hypertension, T2DM and asthma/COPD, regardless of age groups. This study reflects the potential of PIONEER as a federated network of databases that may be used to harness big data in PCa research.

Indexed as

common data modeldata networkobservational researchpalliative managementprostate cancerreal world data

Identifiers

PMID40115485
PMCPMC11921962

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.